- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03703063
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability, and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer.
Subjects must have a newly diagnosed resectable or borderline resectable pancreatic ductal cancer and meet all inclusion/exclusion criteria.
Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be administered on days 1,8, and 15 with NAPOLI will be administered on days 1 and 15.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Vincent J Picozzi, MD
- Phone Number: 206-223-6193
- Email: Vincent.Picozzi@virginiamason.org
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98101
- Recruiting
- Virginia Mason Medical Center
-
Contact:
- Vincent J Picozzi, MD
- Phone Number: 206-223-6193
- Email: Vincent.Picozzi@virginiamason.org
-
Principal Investigator:
- Vincent Picozzi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically proven resectable or borderline resectable pancreatic cancer per current NCCN criteria (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0/1.
Adequate bone marrow reserves as evidenced by:
- absolute neutrophil count (ANC) ≥1,500 cells/μl without the use of hematopoietic growth factors; and
- Platelet count ≥100,000 cells/μl; and
- Hemoglobin ≥9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL).
Adequate hepatic function as evidenced by:
- Serum total bilirubin within normal range for the institution (biliary drainage is allowed for biliary obstruction); and
aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
- 2.5 x upper limit of normal (ULN) (≤5 x ULN is acceptable if liver metastases are present).
- Adequate renal function as evidenced by a serum creatinine ≤1.5 x ULN.
- At least 18 years of age.
- Women of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must: Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting study medications (including dose interruptions) and for 3 months after last dose of study medication and Have a negative pregnancy test result at screening and agree to ongoing pregnancy testing at the Investigator's discretion during the course of the study. This applies even if the subject practices true abstinence from heterosexual contact.
- Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with study medications and for 3 months following the last dose of study medication, even if he has undergone a successful vasectomy.
Exclusion Criteria:
- Prior therapy for pancreatic cancer (e.g., attempted surgery, chemotherapy, radiation therapy).
- Any contraindication to curative surgery.
- History of any second malignancy in the last 5 years except in-situ cancer or basal or squamous cell skin cancer. Subjects with history of other malignancies are eligible if they have been continuously disease free for at least 5 years.
- Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before study participation.
- New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure.
- Active infection or an unexplained fever >38.5°C during screening visit or on the first scheduled day of dosing in each cycle which, in the Investigator's opinion, might compromise the subject's participation in the trial or affect the study outcome. Subjects with tumor fever may be enrolled at the discretion of the Investigator.
- Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin.
- Neuropathy > grade 1.
- Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
- Any other medical or social condition deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and/or participate in the study in any way, or interfere with the interpretation of the results.
- Inability or unwillingness to provide written informed consent.
- Patients who are not appropriate candidates for participation in this clinical study for any other reason as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resectable patients
Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
|
Administered by intravenous infusion over 30 minutes.
Other Names:
Administered by intravenous infusion over 30-40 minutes.
Other Names:
Administered by intravenous infusion over 90 minutes.
Administered by intravenous infusion over 30 minutes.
Administered by intravenous infusion over 46 hours.
|
Experimental: Borderline resectable patients
Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
|
Administered by intravenous infusion over 30 minutes.
Other Names:
Administered by intravenous infusion over 30-40 minutes.
Other Names:
Administered by intravenous infusion over 90 minutes.
Administered by intravenous infusion over 30 minutes.
Administered by intravenous infusion over 46 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment safety as assessed by CTCAE v4.03
Time Frame: An average of 1 year
|
Toxicities are evaluated according to CTCAE v4.03
|
An average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
OS is defined as the time between the date of enrollment and the date of death (whatever the cause).
|
5 years
|
Progression free survival (PFS)
Time Frame: 5 years
|
PFS is defined as the time between the date of enrollment and the date of the first radiological and/or pathological progression.
Progression is assessed by investigator according to RECIST v1.1 criteria.
|
5 years
|
Response rate
Time Frame: An average of 1 year
|
Response rate will be assessed per RECIST v1.1 criteria and CA19-9 over the entire treatment period.
|
An average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vincent J Picozzi, MD, Virginia Mason Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Gemcitabine
- Paclitaxel
- Leucovorin
Other Study ID Numbers
- CRP17118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting